Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05595642 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,290
- Enrollment target
- 20
- Study locations
NCT05595642 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 1,290 participants, above the 615-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (110% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT05595642, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,290 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Astegolimab
Study Locations (20)
Florida
- Cornerstone Research Institute - Altamonte Springs
- Invictus Clinical Research Group, LLC - Coconut Creek
- Finlay Medical Research Corporation - Greenacres City
- San Marcus Research Clinic Inc. - Miami
- Oceane7 Medical & Research Center, Inc. - Miami
- Avantis Clinical Research, LLC - Miami
- Research Institute of South Florida Inc - Miami
Alabama
- Pinnacle Research Group - Anniston
- AllerVie Clinical Research - Birmingham
- Synexus Clinical Research US, Inc. - Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
- SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS - Dothan
California
- Kern Research - Bakersfield
- VA Palo Alto Health Care System - Palo Alto
- AES - DRS - Synexus Clinical Research US, Inc. - Vista - Vista
- Allergy & Asthma Medical Group of the Bay Area - Walnut Creek
Arizona
- Pulmonary Associates PA - Glendale
- Synexus Clinical Research US, Inc. - Phoenix West - Glendale
- AES - DRS - Synexus Clinical Research US, Inc. - Tucson - Tucson
Arkansas
- Lynn Institute of The Ozarks - ERN - PPDS - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,290 participants |
| Start Date | 2022-12-29 |
| Est. Completion | 2027-09-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05595642
The ClinicalTrials.gov registry entry for NCT05595642 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,290 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 615-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (110% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05595642 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT05595642 about?
NCT05595642 is a clinical study titled "A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease". This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
What is the current status of trial NCT05595642?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,290 participants. The study started on 2022-12-29. Estimated completion is 2027-09-24.
What conditions does trial NCT05595642 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT05595642?
The interventions under investigation include: Placebo (DRUG), Astegolimab (DRUG).
Who is sponsoring clinical trial NCT05595642?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05595642 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.